Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25183128 | 1.00 | ITGB3 (0.53) | ITGB3ITGA2BTSHRCTSKCTSS | |
| SCHEMBL25186364 | 0.99 | ITGB3 (0.54) | ITGB3ITGA2BTSHRCTSKCTSS | |
| SCHEMBL8717338 | 0.99 | ITGB3 (0.54) | ITGB3ITGA2BTSHRCTSKCTSS | |
| SCHEMBL25177957 | 0.88 | CTSK (0.48) | ITGB3ITGA2BTSHRCTSKCTSS | |
| SCHEMBL7298353 | 0.87 | CYP2D6 (0.46) | ITGB3ITGA2BTSHRCTSKCTSS | |
| SCHEMBL25186006 | 0.87 | ITGB3 (0.49) | ITGB3ITGA2BTSHRCTSKCTSS | |
| SCHEMBL25185744 | 0.87 | ITGB3 (0.45) | ITGB3ITGA2BTSHRCTSKCTSS | |
| SCHEMBL25186542 | 0.85 | ITGB3 (0.48) | ITGB3ITGA2BTSHRCTSKCTSS | |
| SCHEMBL23845159 | 0.85 | HRH2 (0.48) | ITGB3ITGA2BTSHRCTSKCTSS | |
| SCHEMBL1707105 | 0.85 | CTSK (0.54) | ITGB3ITGA2BTSHRCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687492-B2 | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | ITGB3 2369/4885ITGA2B 3916/4885TSHR 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.